125 related articles for article (PubMed ID: 35802950)
1. Corrigendum to 'Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study': [ESMO Open Volume 6, Issue 4, August 2021, 100191].
Hotta K; Saeki S; Yamaguchi M; Harada D; Bessho A; Tanaka K; Inoue K; Gemba K; Shiojiri M; Kato Y; Ninomiya T; Kubo T; Kishimoto J; Shioyama Y; Katsui K; Sasaki J; Kiura K; Sugio K
ESMO Open; 2022 Aug; 7(4):100532. PubMed ID: 35802950
[No Abstract] [Full Text] [Related]
2. Gefitinib induction followed by chemoradiotherapy in EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study.
Hotta K; Saeki S; Yamaguchi M; Harada D; Bessho A; Tanaka K; Inoue K; Gemba K; Shiojiri M; Kato Y; Ninomiya T; Kubo T; Kishimoto J; Shioyama Y; Katsui K; Sasaki J; Kiura K; Sugio K
ESMO Open; 2021 Aug; 6(4):100191. PubMed ID: 34153652
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
Hotta K; Sasaki J; Saeki S; Takigawa N; Katsui K; Takayama K; Nogami N; Shioyama Y; Bessho A; Kishimoto J; Tanimoto M; Kiura K; Ichinose Y
Clin Lung Cancer; 2016 Jan; 17(1):75-9. PubMed ID: 26387039
[TBL] [Abstract][Full Text] [Related]
4. Corrigendum to 'Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study': [ESMO Open Volume 7, Issue 2, April 2022, 100466].
Sinn K; Mosleh B; Steindl A; Zoechbauer-Mueller S; Dieckmann K; Widder J; Steiner E; Klepetko W; Hoetzenecker K; Laszlo V; Dome B; Klikovits T; Hoda MA
ESMO Open; 2022 Jun; 7(3):100523. PubMed ID: 35696745
[No Abstract] [Full Text] [Related]
5. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Ready N
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy combined with gefitinib for patients with locally advanced non-small cell lung cancer who are unfit for surgery or concurrent chemoradiotherapy: a phase II clinical trial.
Fu Z; Yang X; Wang W; Deng L; Zhang T; Bi N; Wang X; Chen D; Zhou Z; Wang L; Liang J
Radiat Oncol; 2020 Jun; 15(1):155. PubMed ID: 32563259
[TBL] [Abstract][Full Text] [Related]
7. Locally advanced cervical cancer - neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: A phase II study.
Benson R; Pathy S; Kumar L; Mathur S; Dadhwal V; Mohanti BK
J Cancer Res Ther; 2019; 15(6):1359-1364. PubMed ID: 31898673
[TBL] [Abstract][Full Text] [Related]
8. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
10. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
[TBL] [Abstract][Full Text] [Related]
11. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer.
Giorgio CG; Pappalardo A; Russo A; Santini D; Di Rosa C; Di Salvo C; Castorina S; Marletta F; Bellissima G; Palermo N; Scuderi C; Bordonaro R
Anticancer Drugs; 2007 Jul; 18(6):713-9. PubMed ID: 17762402
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
Yu W; Ye F; Yuan X; Ma Y; Mao C; Li X; Li J; Dai C; Qian F; Li J; Fan X; Zhou Y; Wang D; Guo Z; An H; Zhang M; Chen D; Xia S
BMC Cancer; 2021 Jul; 21(1):877. PubMed ID: 34332557
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.
Sanford M; Scott LJ
Drugs; 2009 Nov; 69(16):2303-28. PubMed ID: 19852530
[TBL] [Abstract][Full Text] [Related]
16. Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
Li N; Ou W; Ye X; Sun HB; Zhang L; Fang Q; Zhang SL; Wang BX; Wang SY
Ann Surg Oncol; 2014 Jun; 21(6):2091-6. PubMed ID: 24585406
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
19. Aumolertinib: A Review in Non-Small Cell Lung Cancer.
Shirley M; Keam SJ
Drugs; 2022 Apr; 82(5):577-584. PubMed ID: 35305259
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
